Skip to content
Screener

OptimizeRx OPRX Q1 2025 earnings

Reported May 12, 2025 · After market close

Revenue$21.9MBeat by $3.2M
EPS$0.08Beat by $0.19
Revenue estimate$18.7M
EPS estimate-$0.11

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$21.6M
EPS estimate$0.19

Financials

Q1 2025

Income statement

See full
Revenue$21.9M+1,168,770%
Gross profit$13.3M+278%
Operating income-$2.1M+58.2%
Net income-$2.2M+68.1%
EPS (diluted)-$0.12+68.4%

Balance sheet

See full
Cash & equivalents$16.6M+9.2%
Total debt$32.8M-8.7%
Total equity$116.3M-5.1%
Total assets$167.8M-4.9%

Cash flow

See full
Operating cash flow$3.9M+82.4%
CapEx$27.0K-15.6%
Free cash flow$3.8M+83.9%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$160.13M-27.4%
Enterprise value$176.35M-26.9%
P/S2.1×-1.7×

Profitability

See full
Gross margin55.9%+8.1pp
Net margin-20.1%-5.2pp
FCF margin8.5%—

Returns & leverage

See full
Return on equity-12.9%-1.4pp
Debt / equity0.3×0.0×
Current ratio2.8×-0.1×

Segments

By product

See full
Solutions Sold On A Commissions Bases, Agent Revenue Recognized On A Net Basis$3.4M—

FAQ

When did OptimizeRx report Q1 2025 earnings?
OptimizeRx (OPRX) reported Q1 2025 earnings on May 12, 2025 after market close.
What were OptimizeRx's Q1 2025 revenue and EPS?
OptimizeRx reported revenue of $21.9M and eps of $0.08 for Q1 2025.
Did OptimizeRx beat estimates in Q1 2025?
Revenue beat the consensus estimate of $18.7M by $3.2M. EPS beat the consensus estimate of $-0.11 by $0.19.
How did OptimizeRx's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 11.4% from $19.7M a year earlier.
Where can I find OptimizeRx's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001448431-25-000003) and the 10-Q periodic report (0001448431-25-000005) directly on SEC EDGAR. The filing index links above go to sec.gov.